Literature DB >> 3496626

Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study.

G Di Chiro, J Hatazawa, D A Katz, H V Rizzoli, D J De Michele.   

Abstract

Seventeen patients with intracranial meningiomas were studied with positron emission tomography and fluorine-18-2-fluorodeoxyglucose (PET-FDG) to assess the glucose utilization of these tumors. Four meningiomas followed for 3-5 years after PET-FDG and surgery showed no evidence of recurrence. These tumors had significantly lower glucose utilization rates (1.9 mg/dl/min +/- 1.0) than 11 recurrent or regrowing meningiomas (4.5 mg/dl/min +/- 1.96) (P less than .01). The glucose metabolic rates of meningiomas correlated with tumor growth, as estimated from changes in tumor size on repeated computed tomographic scans. Histopathologically, a syncytial (atypical) meningioma had the highest glucose utilization rate, followed by a papillary meningioma and an angioblastic meningioma. Individual transitional and syncytial (typical) meningiomas showed marked differences in glucose metabolism despite similar microscopic appearance. Glucose utilization rate appears to be at least as reliable as histologic classification and other proposed criteria for predicting the behavior and recurrence of intracranial meningiomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496626     DOI: 10.1148/radiology.164.2.3496626

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  50 in total

1.  Intracranial malignant meningioma with abdominal metastases associated with hypoglycemic shock: a case report.

Authors:  D Yoshida; Y Sugisaki; T Tamaki; N Saitoh; Y Node; T Shimura; A Teramoto
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Metabolic patterns in meningiomas.

Authors:  Birgit Herting; Jürgen Meixensberger; Wolfgang Roggendorf; Heinz Reichmann
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

3.  Management of intracranial meningeal hemangiopericytomas: outcome and experience.

Authors:  K N Fountas; E Kapsalaki; M Kassam; C H Feltes; V G Dimopoulos; J S Robinson; J R Smith
Journal:  Neurosurg Rev       Date:  2006-01-04       Impact factor: 3.042

4.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 5.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

7.  18F-FDG-PET-CT imaging findings of recurrent intracranial haemangiopericytoma with distant metastases.

Authors:  W S W Chan; J Zhang; P L Khong
Journal:  Br J Radiol       Date:  2010-08       Impact factor: 3.039

8.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 9.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

10.  Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.

Authors:  Patricia Guevara; Elizabeth Escobar-Arriaga; David Saavedra-Perez; Abelardo Martinez-Rumayor; Diana Flores-Estrada; Daniel Rembao; Alejandra Calderon; Julio Sotelo; Oscar Arrieta
Journal:  J Neurooncol       Date:  2009-12-15       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.